Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs

February 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

NEW YORK--Physicians and patients contribute to undertreatment of both cancer-related and acute noncancer pain because of unwarranted fear of addiction to pain medications, according to an expert on pain management.

NEW YORK--Physicians and patients contribute to undertreatmentof both cancer-related and acute noncancer pain because of unwarrantedfear of addiction to pain medications, according to an experton pain management.

Despite well-documented evidence that patients are routinely undermedicated,ineffective pain control continues to compromise recovery andquality of life for cancer patients during and after treatment.In fact, said Seddon Savage, MD, director, Outpatient Pain Clinic,Dartmouth-Hitchcock Medical Center, fear of addiction is usuallyunfounded.

"The use of opioids in pain management is permeated withmythology, controversy, and many misunderstandings," shesaid at a media briefing on pain, sponsored by the American MedicalAssociation and Ortho-McNeil Pharmaceutical. She added that oversightby regulatory authorities further inhibits physicians in the useof these drugs.

Dr. Savage said that the fear of addiction is largely unwarranted,since individuals without a history of addictive disease rarelybecome addicted to medication for pain. "Most addicted individualshave a prior personal or family history of addiction of some type,"she said, adding that these individuals likely have a biogeneticpredisposition to addictive disease.

About 10% of the American population has an underlying addictivedisorder, and individuals with one substance dependency are atincreased risk for becoming addicted to another, she noted.

Dr. Savage defined addiction to prescription medication as drug-seekingbehavior characterized by continued use of a drug despite adverseconsequences; preoccupation with obtaining and using the drugwhile failing to comply with other aspects of treatment; and aninability to control the use of medications, including use ofthe drug in higher doses and with greater frequency than the physicianhas prescribed.

Patients with severe pain may engage in drug-seeking behavior,but it differs from addiction in that such behavior ceases assoon as adequate pain control is achieved, she said.

Opioid pain medication can be used safely, even in high dosesand over an extended period of time, if patients are carefullyselected and drug use is consistently monitored. Dr. Savage saidthat cancer-related pain can be managed most effectively withopioids, and there is ample evidence that opioids should be usedaggressively in cancer patients.

Government Scrutiny

In most states, physicians who prescribe opioid pain medicationare subject to oversight by government agencies and medical licensingboards.

"Doctors who prescribe opioids aggressively for pain areheavily scrutinized. Although this is often appropriate, it hasa negative impact on pain control," Dr. Savage said, pointingto cumbersome record-keeping requirements in some states thatcan cause the patient to become a burden to the physician.

Articles in this issue

FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packages
Multidisciplinary Approach Urged For Pain Relief
FDA Approves New Indication for Neupogen: Chronic Neutropenia
Department of Labor Wants to Study Possible Occupation-Cancer Links
Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLC

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 11th 2025
Podcast

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 11th 2025
Article

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.

FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
September 11th 2025
Article
Related Content

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 11th 2025
Podcast

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 11th 2025
Article

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.

FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
September 11th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.